Severe Persistent Asthma Clinical Trial
Official title:
Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.
Neutrophils are implicated in the pathophysiology of multiple asthma phenotypes. It was shown in study IST Q4935s that low-density granulocytes (LDG) are elevated in the blood of patients with moderate or severe asthma. The greatest frequency and the highest percentages of LDG were observed in subjects with severe asthma. The LDG, which were first identified and characterized in systemic lupus erythematosus (SLE) patients, have been reported to display increased cytotoxicity for endothelial cells, increased tendency to form neutrophil extracellular traps, and increased production of tumor necrosis factor (TNF). It was also observed that the LDG expressed increased levels of CD15, which can facilitate attachment of activated platelets to the LDG. Identification of a putative serum biomarker that correlates with increased levels of the CD15+ LDG may be useful for the detection of neutrophil-associated inflammation in severe asthma. Thirty subjects will be screened to identify 20 subjects with severe persistent asthma. The following data and/or samples will then be obtained within three weeks of the clinical assessment: (1) the percentages of LDG will be quantified by flow cytometry; (2) a blood sample will be collected into a PAXgene Blood tube and stored until shipped to Genentech for gene profiling analysis; and (3) a serum sample will be collected for measurement of total immunoglobulin E (IgE) and for future confirmation of potential biomarkers identified in the gene profiling analyses. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01197482 -
Inhaled Steroids and Control of Severe Asthma
|
||
Withdrawn |
NCT02952066 -
Expressions of TRPV1 in Airway of Asthmatics
|
N/A | |
Completed |
NCT02559791 -
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
|
Phase 2/Phase 3 | |
Recruiting |
NCT03617718 -
Project 2 Airway Potential Hydrogen (pH) in Asthma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01839591 -
Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
|
N/A | |
Withdrawn |
NCT00954850 -
A National Program for Severe Asthma: The Canadian Severe Asthma Network
|
N/A | |
Completed |
NCT01748175 -
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
|
||
Withdrawn |
NCT01745809 -
Bronchoscopy Study for Severe Asthma
|
N/A | |
Completed |
NCT02717689 -
A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma
|
N/A | |
Completed |
NCT01750411 -
Severe Asthma Research Program - Wake Forest University
|
||
Completed |
NCT01862289 -
Prevalence of Hyperventilation Syndrome in Difficult Asthma
|
N/A | |
Withdrawn |
NCT00689806 -
Evaluation of Lovastatin in Severe Persistent Asthma
|
Phase 1/Phase 2 |